<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39461916</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>27</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Print">2193-8229</ISSN><JournalIssue CitedMedium="Print"><PubDate><Year>2024</Year><Month>Oct</Month><Day>26</Day></PubDate></JournalIssue><Title>Infectious diseases and therapy</Title><ISOAbbreviation>Infect Dis Ther</ISOAbbreviation></Journal><ArticleTitle>Pharmacovigilance of Drug-Drug Interactions with Nirmatrelvir/Ritonavir.</ArticleTitle><ELocationID EIdType="doi" ValidYN="Y">10.1007/s40121-024-01050-w</ELocationID><Abstract><AbstractText Label="INTRODUCTION" NlmCategory="BACKGROUND">Nirmatrelvir/ritonavir (NMV/r) is approved in the United States (US) and more than 70 other countries for the treatment of mild to moderate COVID-19 in nonhospitalized adults at high risk for severe disease. Because ritonavir inhibits several drug metabolizing enzymes, potential drug-drug interactions (DDIs) between ritonavir and concomitant medications are an important consideration for prescribers. Here, we conducted a real-world analysis of data from Pfizer's global safety database regarding adverse events (AEs) reported during use of NMV/r concomitantly with potentially interacting drugs.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">Data were extracted regarding DDI cases occurring from the start of NMV/r authorization through October 31, 2023. Results regarding concomitant treatment, specific AEs, and clinical outcomes are summarized. Overall NMV/r exposure was estimated based on packs of medication dispensed and was used to calculate reporting rates.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">Among 19,617,670 patients exposed globally to NMV/r, 966 cases of potential DDIs were reported. Of these, 594 occurred in the US against an estimated US exposure of 14,646,990 patients, representing a reporting rate of 0.004%. Globally and in the United States, 66.8% and 77.3% of cases, respectively, were nonserious. Simvastatin and tacrolimus were the most frequently reported drugs associated with potential DDIs, and the most frequently reported AE regarding a specific event or symptom was dysgeusia (altered sense of taste), an AE known to be associated with NMV/r.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Low reporting rates of DDIs support the potential for NMV/r treatment to be safely managed with careful use of available drug interaction resources to aid in risk mitigation.</AbstractText><CopyrightInformation>© 2024. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Hendrick</LastName><ForeName>Victoria</ForeName><Initials>V</Initials><Identifier Source="ORCID">0000-0003-2364-7395</Identifier><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Pfizer Research and Development, Sandwich, Kent, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pohorylo</LastName><ForeName>Erast</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Pfizer Research and Development, Collegeville, PA, USA. erast.pohorylo@pfizer.com.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Merchant</LastName><ForeName>Lubna</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Pfizer Research and Development, Collegeville, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gerhart</LastName><ForeName>Jackie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Translational Clinical Sciences, Pfizer Research and Development, Collegeville, PA, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arham</LastName><ForeName>Iqra Naz</ForeName><Initials>IN</Initials><AffiliationInfo><Affiliation>US Medical and Scientific Affairs, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Draica</LastName><ForeName>Florin</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>US Medical and Scientific Affairs, Pfizer Inc, New York, NY, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Quercia</LastName><ForeName>Romina</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Global Medical Affairs, Pfizer Ltd, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ayoub</LastName><ForeName>Ayman</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Pfizer Research and Development, Sandwich, Kent, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mehta</LastName><ForeName>Reema</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Worldwide Medical and Safety, Pfizer Research and Development, Peapack, NJ, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>26</Day></ArticleDate></Article><MedlineJournalInfo><Country>New Zealand</Country><MedlineTA>Infect Dis Ther</MedlineTA><NlmUniqueID>101634499</NlmUniqueID><ISSNLinking>2193-6382</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Interactions</Keyword><Keyword MajorTopicYN="N">Nirmatrelvir</Keyword><Keyword MajorTopicYN="N">Ritonavir</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>13</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>9</Month><Day>9</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>7</Hour><Minute>22</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>27</Day><Hour>0</Hour><Minute>23</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39461916</ArticleId><ArticleId IdType="doi">10.1007/s40121-024-01050-w</ArticleId><ArticleId IdType="pii">10.1007/s40121-024-01050-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Couture A, Iuliano AD, Chang HH, et al. Estimating COVID-19 hospitalizations in the United States with surveillance data using a Bayesian hierarchical model: modeling study. JMIR Public Health Surveill. 2022;8(6): e34296. https://doi.org/10.2196/34296 .</Citation><ArticleIdList><ArticleId IdType="doi">10.2196/34296</ArticleId><ArticleId IdType="pubmed">35452402</ArticleId><ArticleId IdType="pmc">9169704</ArticleId></ArticleIdList></Reference><Reference><Citation>World Health Organization. WHO COVID-19 Dashboard. https://covid19.who.int/ . Accessed Dec 21, 2022.</Citation></Reference><Reference><Citation>US Department of Health and Human Services. Emergency Use Authorization Declaration. https://www.federalregister.gov/documents/2020/04/01/2020-06905/emergency-use-authorization-declaration . Accessed Sept 11, 2023.</Citation></Reference><Reference><Citation>US Food and Drug Administration. Coronavirus (COVID-19) Update: FDA Authorizes First Oral Antiviral for Treatment of COVID-19. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-oral-antiviral-treatment-covid-19 . Accessed June 26, 2023.</Citation></Reference><Reference><Citation>Paxlovid. Nirmatrelvir/ritonavir. New York: Pfizer Inc; 2023.</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. Effect of nirmatrelvir/ritonavir versus placebo on COVID-19-related hospitalizations and other medical visits. In: IDWeek 2022. Washington, DC, USA; 2022.</Citation></Reference><Reference><Citation>Hammond J, Leister-Tebbe H, Gardner A, et al. Oral nirmatrelvir for high-risk, nonhospitalized adults with Covid-19. N Engl J Med. 2022;386(15):1397–408. https://doi.org/10.1056/NEJMoa2118542 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2118542</ArticleId><ArticleId IdType="pubmed">35172054</ArticleId></ArticleIdList></Reference><Reference><Citation>Leister-Tebbe H, Bao W, Fountaine R, et al. Nirmatrelvir/ritonavir versus placebo in unvaccinated and vaccinated high-risk patients. In: IDWeek. Boston. 2023.</Citation></Reference><Reference><Citation>US Food &amp; Drug Administration. FDA Approves First Oral Antiviral for Treatment of COVID-19 in Adults. https://www.fda.gov/news-events/press-announcements/fda-approves-first-oral-antiviral-treatment-covid-19-adults . Accessed Mar 1, 2024.</Citation></Reference><Reference><Citation>US Food and Drug Administration. Fact Sheet for Healthcare Providers: Emergency Use Authorization for Paxlovid<sup>TM</sup>. https://labeling.pfizer.com/ShowLabeling.aspx?id=16474 . Accessed Mar 23, 2023.</Citation></Reference><Reference><Citation>European Medicines Agency. Summary of Product Characteristics: Paxlovid. https://www.ema.europa.eu/en/documents/product-information/paxlovid-epar-product-information_en.pdf . Accessed Oct 21, 2022.</Citation></Reference><Reference><Citation>Pfizer Inc. Pfizer's PAXLOVID Receives FDA Approval for Adult Patients at High Risk of Progression to Severe COVID-19. https://www.pfizer.com/news/press-release/press-release-detail/pfizers-paxlovidtm-receives-fda-approval-adult-patients . Accessed Feb 27, 2024.</Citation></Reference><Reference><Citation>Aggarwal NR, Molina KC, Beaty LE, et al. Real-world use of nirmatrelvir-ritonavir in outpatients with COVID-19 during the era of omicron variants including BA.4 and BA.5 in Colorado, USA: a retrospective cohort study. Lancet Infect Dis. 2023;23(6):696–705. https://doi.org/10.1016/S1473-3099(23)00011-7 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00011-7</ArticleId><ArticleId IdType="pubmed">36780912</ArticleId><ArticleId IdType="pmc">10014040</ArticleId></ArticleIdList></Reference><Reference><Citation>Cha-Silva AS, Gavaghan M, Nguyen JL, et al. A systematic literature review evaluating real-world use of nirmatrelvir-ritonavir for the prevention of COVID-19-related hospitalization and death. In: IDWeek. Boston. 2023.</Citation></Reference><Reference><Citation>Dryden-Peterson S, Kim A, Kim AY, et al. Nirmatrelvir plus ritonavir for early COVID-19 in a large U.S. health system: a population-based cohort study. Ann Intern Med. 2023;176(1):77–84. https://doi.org/10.7326/m22-2141 .</Citation><ArticleIdList><ArticleId IdType="doi">10.7326/m22-2141</ArticleId><ArticleId IdType="pubmed">36508742</ArticleId></ArticleIdList></Reference><Reference><Citation>Ganatra S, Dani SS, Ahmad J, et al. Oral nirmatrelvir and ritonavir in nonhospitalized vaccinated patients with coronavirus disease 2019. Clin Infect Dis. 2022;76(4):563–72. https://doi.org/10.1093/cid/ciac673 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/cid/ciac673</ArticleId></ArticleIdList></Reference><Reference><Citation>Lewnard JA, McLaughlin JM, Malden D, et al. Effectiveness of nirmatrelvir-ritonavir in preventing hospital admissions and deaths in people with COVID-19: a cohort study in a large US health-care system. Lancet Infect Dis. 2023;23(7):806–15. https://doi.org/10.1016/S1473-3099(23)00118-4 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S1473-3099(23)00118-4</ArticleId><ArticleId IdType="pubmed">36933565</ArticleId><ArticleId IdType="pmc">10081864</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah MM, Joyce B, Plumb ID, et al. Paxlovid associated with decreased hospitalization rate among adults with COVID-19—United States, April–September 2022. MMWR Morb Mortal Wkly Rep. 2022;71(48):1531–7. https://doi.org/10.15585/mmwr.mm7148e2 .</Citation></Reference><Reference><Citation>Owen DR, Allerton CM, Anderson AS, et al. An oral SARS-CoV-2 M<sup>pro</sup> inhibitor clinical candidate for the treatment of COVID-19. Science (New York, NY). 2021;374(6575):1586–93.</Citation><ArticleIdList><ArticleId IdType="doi">10.1126/science.abl4784</ArticleId></ArticleIdList></Reference><Reference><Citation>Sevrioukova IF, Poulos TL. Structure and mechanism of the complex between cytochrome P4503A4 and ritonavir. Proc Natl Acad Sci USA. 2010;107(43):18422–7. https://doi.org/10.1073/pnas.1010693107 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1073/pnas.1010693107</ArticleId><ArticleId IdType="pubmed">20937904</ArticleId><ArticleId IdType="pmc">2973003</ArticleId></ArticleIdList></Reference><Reference><Citation>Norvir. Ritonavir. North Chicago: AbbVie, Inc.; 2022.</Citation></Reference><Reference><Citation>Foisy MM, Yakiwchuk EM, Hughes CA. Induction effects of ritonavir: implications for drug interactions. Ann Pharmacother. 2008;42(7):1048–59. https://doi.org/10.1345/aph.1K615 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1345/aph.1K615</ArticleId><ArticleId IdType="pubmed">18577765</ArticleId></ArticleIdList></Reference><Reference><Citation>Kharasch ED, Bedynek PS, Walker A, Whittington D, Hoffer C. Mechanism of ritonavir changes in methadone pharmacokinetics and pharmacodynamics: II. Ritonavir effects on CYP3A and P-glycoprotein activities. Clin Pharmacol Ther. 2008;84(4):506–12. https://doi.org/10.1038/clpt.2008.102 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/clpt.2008.102</ArticleId><ArticleId IdType="pubmed">19238656</ArticleId></ArticleIdList></Reference><Reference><Citation>Shitara Y, Takeuchi K, Horie T. Long-lasting inhibitory effects of saquinavir and ritonavir on OATP1B1-mediated uptake. J Pharm Sci. 2013;102(9):3427–35. https://doi.org/10.1002/jps.23477 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jps.23477</ArticleId><ArticleId IdType="pubmed">23440887</ArticleId></ArticleIdList></Reference><Reference><Citation>Quercia R, Di Perri G, Pein C, et al. Ritonavir: 25 years’ experience of concomitant medication management. A narrative review. Infect Dis Ther. 2024. https://doi.org/10.1007/s40121-024-00959-6 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40121-024-00959-6</ArticleId><ArticleId IdType="pubmed">38609668</ArticleId><ArticleId IdType="pmc">11098990</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DS, Rehman M, Khan T, et al. Effects of nirmatrelvir/ritonavir on midazolam and dabigatran pharmacokinetics in healthy participants. Br J Clin Pharmacol. 2023;89(11):3352–63. https://doi.org/10.1111/bcp.15835 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15835</ArticleId><ArticleId IdType="pubmed">37354048</ArticleId></ArticleIdList></Reference><Reference><Citation>Cox DS, Van Eyck L, Pawlak S, et al. Effects of itraconazole and carbamazepine on the pharmacokinetics of nirmatrelvir/ritonavir in healthy adults. Br J Clin Pharmacol. 2023;89(9):2867–76. https://doi.org/10.1111/bcp.15788 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/bcp.15788</ArticleId><ArticleId IdType="pubmed">37184075</ArticleId></ArticleIdList></Reference><Reference><Citation>Beyzarov E, Chen Y, Julg R, et al. Global safety database summary of COVID-19-related drug utilization-safety surveillance: a sponsor’s perspective. Drug Saf. 2021;44(1):95–105. https://doi.org/10.1007/s40264-020-01035-x .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s40264-020-01035-x</ArticleId><ArticleId IdType="pubmed">33354753</ArticleId></ArticleIdList></Reference><Reference><Citation>Administration for Strategic Preparedness &amp; Response. COVID-19 Therapeutics Locator. https://covid-19-therapeutics-locator-dhhs.hub.arcgis.com/ . Accessed Jan 4, 2024.</Citation></Reference><Reference><Citation>Simvastatin orally disintegrating tablets. Simvastatin. Research Triangle Park: Synthon Pharmaceuticals; 2007.</Citation></Reference><Reference><Citation>Amlodipine orally disintegrating tablets. Amlodipine besylate salts. Research Triangle Park: Synthon Pharmaceuticals; 2007.</Citation></Reference><Reference><Citation>Uroxatral. Alfuzosin HCl. Bridgewater: Sanofi-Aventis; 2011.</Citation></Reference><Reference><Citation>Wellbutrin. Bupropion hydrochloride. Research Triangle Park: GlaxoSmithKlne; 2017.</Citation></Reference><Reference><Citation>Altoprev. Lovastatin extended-release. Zug: Covis Pharma US, Inc; 2020.</Citation></Reference><Reference><Citation>Lipitor. Atorvastatin calcium. New York: Pfizer Inc; 2020.</Citation></Reference><Reference><Citation>Crestor. Rosuvastatin calcium. Wilmington: AstraZeneca Pharmaceuticals; 2020.</Citation></Reference><Reference><Citation>Prograf. Tacrolimus. Northbrook: Astellas Pharma; 2022.</Citation></Reference><Reference><Citation>Tegretol. Carbamazepine USP. East Hanover: Novartis Pharaceuticals; 2023.</Citation></Reference><Reference><Citation>Drugs.com. Tambocor. Flecainide acetate. Scottsdale: Medicis, The Dermatology Company; 2023.</Citation></Reference><Reference><Citation>Kaletra. Lopinavir and ritonavir. Chicago: AbbVie Inc.; 2023.</Citation></Reference><Reference><Citation>Prezista. Darunavir. Horsham: Janssen Pharmaceuticals; 2023.</Citation></Reference><Reference><Citation>Centers for Disease Control and Prevention. Symptoms of COVID-19. https://www.cdc.gov/coronavirus/2019-ncov/symptoms-testing/symptoms.html . Accessed Jan 10, 2024.</Citation></Reference><Reference><Citation>Prikis M, Cameron A. Paxlovid (nirmatelvir/ritonavir) and tacrolimus drug–drug interaction in a kidney transplant patient with SARS-2-CoV infection: a case report. Transpl Proc. 2022;54(6):1557–60. https://doi.org/10.1016/j.transproceed.2022.04.015 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2022.04.015</ArticleId></ArticleIdList></Reference><Reference><Citation>Kwon EJ, Yun GA, Park S, et al. Treatment of acute tacrolimus toxicity with phenytoin after Paxlovid (nirmatrelvir/ritonavir) administration in a kidney transplant recipient. Kidney Res Clin Pract. 2022;41(6):768–70. https://doi.org/10.23876/j.krcp.22.218 .</Citation><ArticleIdList><ArticleId IdType="doi">10.23876/j.krcp.22.218</ArticleId><ArticleId IdType="pubmed">36474331</ArticleId><ArticleId IdType="pmc">9731781</ArticleId></ArticleIdList></Reference><Reference><Citation>Modi S, Kahwash R, Kissling K. Case report: tacrolimus toxicity in the setting of concurrent Paxlovid use in a heart-transplant recipient. Eur Heart J Case Rep. 2023;7(5):ytad193. https://doi.org/10.1093/ehjcr/ytad193 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/ehjcr/ytad193</ArticleId><ArticleId IdType="pubmed">37252201</ArticleId><ArticleId IdType="pmc">10220502</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah A, Nasrullah A, Butt MA, Young M. Paxlovid with caution: novel case of paxlovid-induced tacrolimus toxicity in a cardiac transplant patient. Eur J Case Rep Intern Med. 2022;9(9): 003528. https://doi.org/10.12890/2022_003528 .</Citation><ArticleIdList><ArticleId IdType="doi">10.12890/2022_003528</ArticleId><ArticleId IdType="pubmed">36299835</ArticleId><ArticleId IdType="pmc">9586497</ArticleId></ArticleIdList></Reference><Reference><Citation>Sindelar M, McCabe D, Carroll E. Tacrolimus drug–drug interaction with nirmatrelvir/ritonavir (Paxlovid™) managed with phenytoin. J Med Toxicol. 2023;19(1):45–8. https://doi.org/10.1007/s13181-022-00922-2 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s13181-022-00922-2</ArticleId><ArticleId IdType="pubmed">36536192</ArticleId></ArticleIdList></Reference><Reference><Citation>Stawiarski K, Avery R, Strout S, Umapathi P. Risks of paxlovid in a heart transplant recipient. J Heart Lung Transplant. 2023;42(1):30–2. https://doi.org/10.1016/j.healun.2022.08.029 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.healun.2022.08.029</ArticleId><ArticleId IdType="pubmed">36344373</ArticleId></ArticleIdList></Reference><Reference><Citation>Young C, Papiro T, Greenberg JH. Elevated tacrolimus levels after treatment with nirmatrelvir/ritonavir (Paxlovid) for COVID-19 infection in a child with a kidney transplant. Pediatr Nephrol. 2023;38(4):1387–8. https://doi.org/10.1007/s00467-022-05712-0 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00467-022-05712-0</ArticleId><ArticleId IdType="pubmed">35982345</ArticleId></ArticleIdList></Reference><Reference><Citation>Pfizer Inc. Important Prescribing Information. Subject: Paxlovid Emergency Use Authorization (EUA) Dosing and Dispensing in Moderate Renal Impairment, and Risk of Serious Adverse Reactions due to Drug Interactions. https://www.paxlovidhcp.com/files/Jan-11-2022_V2-DHCP-letter.pdf . Accessed Mar 10, 2024.</Citation></Reference><Reference><Citation>Pfizer Inc. Important Prescribing Information. Subject: Updated Contraindications Related to Drug Interactions Associated with Paxlovid (nirmatrelvir tablets; ritonavir tablets). https://www.paxlovidhcp.com/files/Updated-Contraindications-Letter-for-Healthcare-Providers_June-2022.pdf Accessed Mar 10, 2024.</Citation></Reference><Reference><Citation>National Institutes of Health. COVID-19 Treatment Guidelines: Drug-Drug Interactions Between Ritonavir-Boosted Nirmatrelvir (Paxlovid) and Concomitant Medications. https://www.covid19treatmentguidelines.nih.gov/therapies/antivirals-including-antibody-products/ritonavir-boosted-nirmatrelvir--paxlovid-/paxlovid-drug–drug-interactions/ . Accessed Feb 26, 2024.</Citation></Reference><Reference><Citation>Pfizer Inc. Drug Interaction Checker. http://pfizer.chcshare.net/COVID-19/1000%20Manuscripts/COV-RWD-1067%20-%20Paxlovid%20post%20marketing%20safety/References/Pfizer%20Drug%20Interaction%20Checker.JPG . Accessed Sept 13, 2023.</Citation></Reference><Reference><Citation>Pfizer Inc. Potentially Significant Drug Interactions, including Contraindicated Drugs: Nirmatrelvir tablets; Ritonavir tablets (PAXLOVID<sup>TM</sup>). http://pfizer.chcshare.net/COVID-19/1000%20Manuscripts/COV-RWD-1067%20-%20Paxlovid%20post%20marketing%20safety/References/Pfizer%20Drug%20Interaction%20Resource.pdf . Accessed Sept 13, 2023.</Citation></Reference><Reference><Citation>Gerhart J, Draica F, Benigno M, et al. Real-world evidence of the top 100 prescribed drugs in the USA and their potential for drug interactions with nirmatrelvir; ritonavir. AAPS J. 2023;25(5):73. https://doi.org/10.1208/s12248-023-00832-3 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1208/s12248-023-00832-3</ArticleId><ArticleId IdType="pubmed">37468770</ArticleId></ArticleIdList></Reference><Reference><Citation>US Food and Drug Administration. PAXLOVID Patient Eligibility Screening Checklist Tool for Prescribers. https://www.fda.gov/media/158165/download . Accessed Sept 13, 2023.</Citation></Reference><Reference><Citation>Uniiversity of Liverpool. COVID-19 Drug Interactions. https://www.covid19-druginteractions.org/checker . Accessed Sept 13, 2023.</Citation></Reference><Reference><Citation>Fisher CD, Lickteig AJ, Augustine LM, et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab Dispos. 2009;37(10):2087–94. https://doi.org/10.1124/dmd.109.027466 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1124/dmd.109.027466</ArticleId><ArticleId IdType="pubmed">19651758</ArticleId><ArticleId IdType="pmc">2769034</ArticleId></ArticleIdList></Reference><Reference><Citation>Morgan ET. Regulation of cytochromes P450 during inflammation and infection. Drug Metab Rev. 1997;29(4):1129–88. https://doi.org/10.3109/03602539709002246 .</Citation><ArticleIdList><ArticleId IdType="doi">10.3109/03602539709002246</ArticleId><ArticleId IdType="pubmed">9421688</ArticleId></ArticleIdList></Reference><Reference><Citation>Jamwal R, de la Monte SM, Ogasawara K, Adusumalli S, Barlock BB, Akhlaghi F. Nonalcoholic fatty liver disease and diabetes are associated with decreased CYP3A4 protein expression and activity in human liver. Mol Pharm. 2018;15(7):2621–32. https://doi.org/10.1021/acs.molpharmaceut.8b00159 .</Citation><ArticleIdList><ArticleId IdType="doi">10.1021/acs.molpharmaceut.8b00159</ArticleId><ArticleId IdType="pubmed">29792708</ArticleId><ArticleId IdType="pmc">7065849</ArticleId></ArticleIdList></Reference><Reference><Citation>National Institutes of Health. Final Coronavirus Disease (COVID-19) Treatment Guidelines (February 29, 2024). https://www.covid19treatmentguidelines.nih.gov/ . Accessed Feb 27, 2024.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle>